Exact Sciences (EXAS) Tops Q2 EPS by 12c, Updates Guidance
Tweet
Share
E-mail
Get Alerts EXAS Hot Sheet
Price: $104.91 --0%
Financial Fact:
Research and development: 7.63M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Financial Fact:
Research and development: 7.63M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.01), $0.12 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $811.1 million versus the consensus estimate of $773.8 million.
GUIDANCE:
Exact Sciences sees FY2025 revenue of $3.13-3.17 billion, versus the consensus of $3.1 billion.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- J Capital Research cautious on Microchip: 'riding high on AI hype but looks weak'
- Chemours reaches $450M settlement over PFAS pollution at four sites
- FDA: approves Pfizer's palbociclib (ibrance) with trastuzumab for HR-positive, her2-positive metastatic breast cancer
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
